D. Mazzoni, L. Wheller, T. Blake
We report the case of a 2-year-old Caucasian boy with a diagnosis of a relapsed malignant rhabdoid tumour who had been recently commenced on panobinostat, a histone deactylase inhibitor that is currently used in clinical trials for the treatment of various haematological conditions. The patient presented with an asymptomatic widespread acneiform eruption primarily affecting the face, with some involvement of the arms, trunks, buttocks and legs. This eruption developed within three weeks of commencing panobinostat and responded to treatment with topical ery- thromycin. This is a rarely reported incidence of an acnei- form eruption associated with a histone deactylase inhibitor in a young child, and the ﬁrst report of a drug eruption secondary to panobinostat.